Catalyst Pharmaceuticals Files 8-K/A Amendment

TL;DR

Catalyst Pharma filed an amendment to its 8-K, updating financial statements/exhibits as of Aug 25, 2025.

AI Summary

Catalyst Pharmaceuticals, Inc. filed an amendment (8-K/A) on August 28, 2025, to its current report originally filed on August 25, 2025. This amendment pertains to financial statements and exhibits, with the date of the earliest event reported being August 25, 2025. The company is incorporated in Delaware and its principal executive offices are located in Coral Gables, Florida.

Why It Matters

This filing indicates an update or correction to previously submitted financial statements or exhibits, which could be important for investors assessing the company's financial health and disclosures.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, likely for administrative or minor correction purposes, rather than a significant event.

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — Registrant
• August 25, 2025 (date) — Date of Earliest Event Reported
• August 28, 2025 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Coral Gables, Florida (location) — Principal Executive Offices

FAQ

From the Filing

0001193125-25-191273.txt : 20250828 0001193125-25-191273.hdr.sgml : 20250828 20250828163037 ACCESSION NUMBER: 0001193125-25-191273 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250825 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250828 DATE AS OF CHANGE: 20250828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 251273998 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K/A 1 d40349d8ka.htm 8-K/A 8-K/A NASDAQ true 0001369568 0001369568 2025-08-25 2025-08-25     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K/A     (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 25, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) 355 Alhambra Circle Suite 801 Coral Gables , Florida (Address of principal executive offices)   33134 (Zip Code) Registrant’s telephone number, including area code: ( 305 ) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       EXPLANATORY NOTE On August 25, 2025, Catalyst Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the U.S. Securities and Exchange Commission reporting that the Company had entered into a settlement agreement with Lupin Pharmaceuticals, Inc. and Lupin Ltd. (“Lupin”) resolving certain patent litigation brought by the Company and SERB S.A. against Lupin